GlobeNewswire: Synthorx, Inc. Contains the last 10 of 20 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T02:19:59ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/11/13/1946299/0/en/Synthorx-to-Present-at-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=52107Synthorx to Present at Upcoming Investor Conferences2019-11-13T13:00:00Z<![CDATA[SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the Company will present at multiple upcoming investor conferences:]]>https://www.globenewswire.com/news-release/2019/11/05/1941634/0/en/Synthorx-Reports-Third-Quarter-Financial-Results.html?f=22&fvtc=4&fvtv=52107Synthorx Reports Third Quarter Financial Results2019-11-05T21:05:00Z<![CDATA[SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today reported financial results and provided a business update for the third quarter ended September 30, 2019.]]>https://www.globenewswire.com/news-release/2019/11/05/1941142/0/en/Synthorx-to-Present-THOR-809-Data-at-the-American-College-of-Rheumatology-ACR-Annual-Meeting.html?f=22&fvtc=4&fvtv=52107Synthorx to Present THOR-809 Data at the American College of Rheumatology (ACR) Annual Meeting2019-11-05T13:00:00Z<![CDATA[SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced that preclinical data highlighting THOR-809 will be presented at the American College of Rheumatology (ACR) Annual Meeting taking place in Atlanta from November 8-13, 2019.]]>https://www.globenewswire.com/news-release/2019/10/29/1937426/0/en/Synthorx-to-Present-at-the-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html?f=22&fvtc=4&fvtv=52107Synthorx to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting2019-10-29T20:05:00Z<![CDATA[SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the presentation of three posters at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting in National Harbor, MD, from November 6-10, 2019. These posters will highlight the company’s lead product candidate THOR-707 and two of its other Synthorin™ cytokines for immuno-oncology.]]>https://www.globenewswire.com/news-release/2019/09/23/1919108/0/en/Synthorx-to-Present-at-the-European-Society-for-Medical-Oncology-ESMO-2019-Congress.html?f=22&fvtc=4&fvtv=52107Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress2019-09-23T12:00:00Z<![CDATA[SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced that preclinical data for immuno-oncology product candidate, THOR-707, will be presented at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, from September 27 through October 1, 2019.]]>https://www.globenewswire.com/news-release/2019/09/09/1912681/0/en/Synthorx-to-Present-at-the-2019-World-Congress-of-Inflammation.html?f=22&fvtc=4&fvtv=52107Synthorx to Present at the 2019 World Congress of Inflammation2019-09-09T12:00:00Z<![CDATA[First-of-its-Kind Genetic Alphabet Platform Used to Design Synthorin for Autoimmune Indications First-of-its-Kind Genetic Alphabet Platform Used to Design Synthorin for Autoimmune Indications]]>https://www.globenewswire.com/news-release/2019/08/29/1908716/0/en/Synthorx-to-Present-at-H-C-Wainwright-21st-Annual-Global-Investment-Conference.html?f=22&fvtc=4&fvtv=52107Synthorx to Present at H.C. Wainwright 21st Annual Global Investment Conference2019-08-29T20:05:00Z<![CDATA[SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the Company will present at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9 at 10:25 a.m. ET in New York, NY.]]>https://www.globenewswire.com/news-release/2019/08/01/1895960/0/en/Synthorx-Reports-Second-Quarter-Financial-Results.html?f=22&fvtc=4&fvtv=52107Synthorx Reports Second Quarter Financial Results2019-08-01T20:05:00Z<![CDATA[SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today reported financial results and provided a business update for the second quarter ended June 30, 2019.]]>https://www.globenewswire.com/news-release/2019/07/24/1887111/0/en/Synthorx-Initiates-Patient-Dosing-in-Australia-and-Announces-Clearance-of-IND-in-the-U-S-for-Lead-Immuno-oncology-Product-Candidate-THOR-707.html?f=22&fvtc=4&fvtv=52107Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-7072019-07-24T12:00:00Z<![CDATA[SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, announced today it has opened HAMMER, a global, Phase 1/2, first-in-human clinical trial of THOR-707, with Australia being the first region to enroll patients to date. In addition, the company has received clearance from the Food and Drug Administration (FDA) for the Investigational New Drug (IND) Application for THOR-707, paving the way for patient enrollment to proceed in the U.S. The single agent and combination arms of the trial are evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of THOR-707 in patients with advanced or metastatic solid tumors.]]>https://www.globenewswire.com/news-release/2019/05/29/1856702/0/en/Synthorx-to-Present-at-Jefferies-2019-Healthcare-Conference.html?f=22&fvtc=4&fvtv=52107Synthorx to Present at Jefferies 2019 Healthcare Conference2019-05-29T20:10:00Z<![CDATA[SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the Company will present at the Jefferies 2019 Healthcare Conference on Wednesday, June 5, 2019 at 9:00 a.m. ET in New York, NY.]]>